New international grants to fuel next-generation malaria vaccines
Empowering regional leaders thorough the Australia Awards Fellowships
Parents and teens prefer conversations over porn-blocking technology
Exploring drug use in older adults: APSAD 2024
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
Exploring the Feasibility and Acceptability of Technological Interventions to Pr...
Stellabody®: A novel hexamer-promoting mutation for improved IgG potency
Dynamic nucleolar targeting of dengue virus polymerase NS5 in response to extrac...
20-year trends in Australian methamphetamine-related deaths, 2001-2020.
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Current Appeal
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Burnet Institute is developing platforms to enhance efficacy of antibodies, Fc-fusion proteins, and antibody-like biologics that have potential application in oncology, infectious disease and immunological conditions.
Find us at BIO 2024 this June.
A hexamerising technology that transforms the potency of monoclonal antibodies (mAb), Fc fusion prot...
